Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1208)	4/23/1999 4:55:00 PM
From: VeloSpeed	Respond to of 1826

Our wedding anniversary on 5/19... hope to have a nice gift for my wife thanks to ASCO. MOGN is looking better every day. -VeloSpeed

To: scaram(o)uche who wrote (1208)	4/23/1999 10:38:00 PM
From: Russian Bear	Respond to of 1826

The following was posted on the Yahoo! thread today. Presumably, it is an excerpt from the ASCO 114 abstract. I cannot verify that this is legitimate. Take it for what it may be worth: <<"Of the 12 patients with evaluable PSA data, 3 patients (25%)have experienced decreases (maximum decrease range 64%-81%)after 1 or 2 courses, 5 patients (42%) have stable PSA levels.>> RB